Michelle A. Silver

Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et autres

AIMS: The objective of this study was to quantify all-cause direct healthcare costs and healthcare resource utilization (HCRU) in the six months before and after COVID-19-associated hospitalization among Medicare fee-for-service (FFS) beneficiaries during the recent Omicron period (March 2023-March 2025). METHODS: This …

us, jp (code pays fourni par la source)

Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et autres

The objective of this study was to quantify all-cause direct healthcare costs and healthcare resource utilization (HCRU) in the six months before and after COVID-19-associated hospitalization among Medicare fee-for-service (FFS) beneficiaries during the recent Omicron period (March 2023–March 2025). This retrospective observational …

Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et autres

The objective of this study was to quantify all-cause direct healthcare costs and healthcare resource utilization (HCRU) in the six months before and after COVID-19-associated hospitalization among Medicare fee-for-service (FFS) beneficiaries during the recent Omicron period (March 2023–March 2025). This retrospective observational …

Mortality and transitions-of-care after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Michelle A. Silver, Han Yu, Santiago M. C. Lopez et autres

BACKGROUND: The patient burden from COVID-19 extends beyond acute hospitalization, especially for older adults. The objective of this study was to describe post-discharge care settings and mortality rates after a COVID-19 hospitalization among adults aged ≥ 65 years in the United States. …

us, jp (code pays fourni par la source)

Additional file 1 of Mortality and transitions-of-care after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et autres

Supplementary Material 1.

us (code pays fourni par la source)

Additional file 1 of Mortality and transitions-of-care after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis

Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et autres

Supplementary Material 1.

us (code pays fourni par la source)

26-A-10557-ACC TEMPORAL IDENTIFICATION OF EARLY COMORBIDITIES FOR ENHANCED DETECTION OF ATTRWT-CM: A MEDICARE ANALYSIS

Justin Lee Grodin, Ann Willet, Haechung Chung, Michelle A. Silver et autres

us, jp (code pays fourni par la source)

Study of Real-World Treatment Patterns in Patients with Sickle Cell Disease Using US Medicaid Claims Data

Xunming Sun, Yun Gu, Budhaditya Goswami, Jamie Ye et autres

Introduction: Sickle cell disease (SCD) is a group of autosomal, codominant, inheritable diseases caused by a single mutation in the gene encoding the beta subunit of hemoglobin (HBB). SCD affects millions of people globally (CDC.gov SCD Data, 2024). Currently approved SCD drugs …

us, in (code pays fourni par la source)

Adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US) based on two claims databases.

Aparna R. Parikh, Maria Cecilia Vieira, Michelle A. Silver, Andrew R. Rava et autres

e23146 Background: The BRAF V600E mutation (BRAF-m) occurs in approximately 7% of patients with metastatic CRC (mCRC). Encorafenib (enco) in combination with cetuximab (cetux) was approved in April 2020 as the first targeted regimen for the treatment of adult patients with mCRC …

us (code pays fourni par la source)

CO32 Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line (1L) Folfirinox (FFX) or Gemcitabine + Nab-paclitaxel (GnP)

Syvart Dennen, Michelle A. Silver, Paul C. Cockrum, G.P. Kim

fr, us (code pays fourni par la source)

Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L).

Syvart Dennen, Michelle A. Silver, Paul C. Cockrum, Ravi Kumar Paluri

e16321 Background: FFX and GnP are the most common 1L treatments for mPDAC. Each regimen is associated with a different profile of toxic effects that impact quality of life. However, the regimens have not been directly compared for safety or efficacy in …

us (code pays fourni par la source)

Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + nab-paclitaxel (GnP) in the first-line (1L).

Ravi Kumar Paluri, Michelle A. Silver, Paul C. Cockrum, Syvart Dennen

e16322 Background: FFX and GnP are the most common 1L treatments for pts with mPDAC. Approximately half of pts treated with these regimens continue to 2L, though optimal 2L treatment is unclear. We identified a RW sample of mPDAC pts treated with …

us (code pays fourni par la source)